KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $40.0 million.

  • Moderna's Receivables - Other fell 2000.0% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of $59.0 million for FY2024, which is 0.0% changed from last year.
  • Per Moderna's latest filing, its Receivables - Other stood at $40.0 million for Q3 2025, which was down 2000.0% from $61.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Receivables - Other ranged from a high of $69.0 million in Q1 2023 and a low of $6.0 million during Q3 2021
  • Moreover, its 5-year median value for Receivables - Other was $54.0 million (2022), whereas its average is $48.3 million.
  • In the last 5 years, Moderna's Receivables - Other plummeted by 4006.59% in 2021 and then skyrocketed by 80000.0% in 2022.
  • Over the past 5 years, Moderna's Receivables - Other (Quarter) stood at $51.0 million in 2021, then rose by 19.61% to $61.0 million in 2022, then dropped by 3.28% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then crashed by 32.2% to $40.0 million in 2025.
  • Its last three reported values are $40.0 million in Q3 2025, $61.0 million for Q2 2025, and $53.0 million during Q1 2025.